Ginkgolide B Blocks Vascular Remodeling after Vascular Injury via Regulating Tgfβ1/Smad Signaling Pathway

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Molecular Medicine

Background:

• Coronary artery disease (CAD) is a leading cause of death globally.
• Vascular remodeling and restenosis commonly occur after percutaneous coronary intervention (PCI).

Purpose of the Study:

• To investigate the efficacy of Ginkgolide B (GB) in preventing vascular remodeling and restenosis.
• To elucidate the underlying molecular mechanisms of GB's action, focusing on the TGF-β1/Smad pathway.

Main Methods:

• Studies were conducted in wild-type mice following left carotid artery (LCA) injury.
• Experiments involved human vascular smooth muscle cells (HVSMAs) and human umbilical vein endothelial cells (HUVECs) in vitro.
• The role of TGF-β1 was assessed using pirfenidone (PFD) and in Tgfβ1-/- mice.

Main Results:

• Ginkgolide B (GB) significantly suppressed vascular remodeling and restenosis in mice.
• GB's protective effects were mediated through the modulation of the TGF-β1/Smad signaling pathway in HVSMAs.
• The therapeutic benefits of GB were diminished by pirfenidone and absent in Tgfβ1-/- mice.

Conclusions:

• Ginkgolide B (GB) is a potential therapeutic agent for preventing vascular remodeling and restenosis post-PCI.
• GB exerts its effects by repressing the TGF-β1/Smad signaling pathway.
• Targeting the TGF-β1/Smad pathway offers a promising strategy for managing restenosis.